- Mustang Bio Inc MBIO has been awarded a grant of approximately $2 million from the National Cancer Institute of the National Institutes of Health (NIH).
- The two-year award will partially fund the Phase 1 trial to assess the safety, tolerability, and efficacy of MB-106 for relapsed or refractory B-cell non-Hodgkin lymphomas or chronic lymphocytic leukemia.
- MB-106 is a CD20-targeted, autologous CAR T cell therapy.
- Related: Mustang Bio's CAR T Cell Therapy Achieves 93% ORR, 67% CR In Mid-Stage Leukemia Trial.
- In addition, the Office for Human Research Protections has approved Federalwide Assurance for Mustang's research for the protection of human subjects in research.
- Price Action: MBIO shares are up 3.98% at $2.32 during the market session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechLong IdeasNewsPenny StocksHealth CareFinancingMoversTrading IdeasGeneralBriefsNon Hodgkin LymphomaPhase 1 Trial
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
